Donepezil hydrochloride (DrugBank: Donepezil)
3 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 4 |
| 124 | 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症 | 3 |
| 156 | レット症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000009958 | 2013/03/08 | 01/03/2013 | Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction | Parkinson's disease | Donepezil hydrochloride added to standard therapy Placebo added to standard therapy | National Hospital Organization, Sendai-Nishitaga Hospital | NULL | Complete: follow-up complete | 55years-old | 75years-old | Male and Female | 200 | Not applicable | Japan | |
| 2 | EUCTR2009-015170-35-GB (EUCTR) | 27/01/2012 | 21/12/2011 | Study across 22 UK hospitals investigating if a drug called Donepezil Hydrochloride can help people with an early form of Parkinson's Disease dementia. | Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD) - Donepezil in Early Dementia Associated with Parkinson's Disease | Parkinson's disease with mild dementia (PDD);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | The Newcastle upon Tyne Hospitals NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 3 | United Kingdom | |||
| 3 | JPRN-UMIN000005403 | 2011/04/01 | 08/04/2011 | A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson Disease | Parkinson disease | 5mg of donepezil hydrochloride placebo | Designated Research, National Hospital Organization | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 142 | Phase 3 | Japan | |
| 4 | JPRN-UMIN000003080 | 2010/01/01 | 30/01/2010 | Double Blind Study for Effects of Donepezil Hydrochloride on Parkinson's Disease | Parkinson's disease | Donepezil hydrochloride (3mg for 2 weeks, 5mg for 2 weeks) Placebo | Clinical Research Center, Utano National Hospital, National Hospital Organization | NULL | Complete: follow-up complete | 40years-old | 75years-old | Male and Female | 30 | Not applicable | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-001162-40-SE (EUCTR) | 01/04/2005 | 03/02/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;United Kingdom;Germany;Spain;Italy;Sweden | |||
| 2 | EUCTR2004-001162-40-FI (EUCTR) | 08/03/2005 | 28/12/2004 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Finland;Spain;Germany;Italy;United Kingdom;Sweden | ||
| 3 | EUCTR2004-001162-40-DE (EUCTR) | 25/01/2005 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0;Level: PT;Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 INN or Proposed INN: donepezil hydrochloride | Eisai Ltd | NULL | Not Recruiting | Female: yes Male: yes | 150 | Finland;Spain;Germany;Italy;United Kingdom;Sweden |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00069550 (ClinicalTrials.gov) | September 2004 | 29/9/2003 | Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome | Pathogenesis of Rett Syndrome: Natural History and Treatment | Rett Syndrome | Drug: dextromethorphan;Drug: donepezil hydrochloride | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Recruiting | 1 Year | 15 Years | Both | 90 | Phase 3 | United States |